Cargando…
Efficacy and safety of Bujing Yishi tablet for glaucoma with controlled IOP: study protocol for a multi-centre randomized controlled trial
BACKGROUND: As an irreversible, intractable disease with vision loss, glaucoma leads to permanent and progressive damage of visual function. Lowering high intraocular pressure (HIOP) is the first choice for treating glaucoma; however, the control of HIOP is not enough to prevent progressive vison lo...
Autores principales: | Liu, Hongji, Li, Xiang, Zhang, Zongduan, Zeng, Jieping, Dai, Yan, Wang, Chao, Xie, Zhao, Cheng, Lin, Cui, Linru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249294/ https://www.ncbi.nlm.nih.gov/pubmed/32450908 http://dx.doi.org/10.1186/s13063-020-04249-7 |
Ejemplares similares
-
Detecting IOP Fluctuations in Glaucoma Patients
por: Nuyen, Brenda, et al.
Publicado: (2016) -
Selective laser trabeculoplasty reduces mean IOP and IOP variation in normal tension glaucoma patients
por: El Mallah, Mohammed K, et al.
Publicado: (2010) -
Significance of non-intraocular pressure (IOP)-related factors particularly in normal tension glaucoma: Looking beyond IOP
por: Dinakaran, Shoruba, et al.
Publicado: (2022) -
Innovative IOP-Independent Neuroprotection and Neuroregeneration Strategies in the Pipeline for Glaucoma
por: Tsai, James C.
Publicado: (2020) -
Inter-eye correlation analysis of 24-h IOPs and glaucoma progression
por: Dakroub, Mohamad, et al.
Publicado: (2022)